Form 4 for KYTX Kyverna Therapeutics, Inc.
Accepted 2026-05-29 16:30:02 ET · period of report 2026-05-27 · accession 0001193125-26-248425 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-05-29 16:30 | 2026-05-27 | KYTX | Aktar Mert | Dir | A - Grant | $0.00 | +5,093 | 21.7K | +31% | $0 |
| D | 2026-05-29 16:30 | 2026-05-27 | KYTX | Aktar Mert | Dir | A - Grant | $0.00 | +20.6K | 20.6K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-05-27 | A | A | 5,093 | $0.00 | 21,727 | D | — | — | (F1) Represents a restricted stock unit award of common stock, which will vest in full on the earlier of (i) May 27, 2027, and (ii) immediately prior to the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive. |
| 2 | Derivative | Stock Option (right to buy) | 2026-05-27 | A | A | 20,582 | $0.00 | 20,582 | D | $8.59 · — to 2036-05-27 | 20,582 Common Stock | (F2) All of the shares subject to the option shall be fully vested and exercisable on the earlier of (i) May 27, 2027, and (ii) immediately prior to the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive. |